167 related articles for article (PubMed ID: 19139117)
1. Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Ihle NT; Lemos R; Schwartz D; Oh J; Halter RJ; Wipf P; Kirkpatrick L; Powis G
Mol Cancer Ther; 2009 Jan; 8(1):94-100. PubMed ID: 19139117
[TBL] [Abstract][Full Text] [Related]
2. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Ihle NT; Paine-Murrieta G; Berggren MI; Baker A; Tate WR; Wipf P; Abraham RT; Kirkpatrick DL; Powis G
Mol Cancer Ther; 2005 Sep; 4(9):1349-57. PubMed ID: 16170026
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt.
Xing B; Xin T; Hunter RL; Bing G
J Neuroinflammation; 2008 Jan; 5():4. PubMed ID: 18205920
[TBL] [Abstract][Full Text] [Related]
4. The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.
Kim SL; Kim EM; Cheong SJ; Lee CM; Kim DW; Jeong HJ; Lim ST; Sohn MH; Yim CY
Nucl Med Biol; 2009 May; 36(4):427-33. PubMed ID: 19423011
[TBL] [Abstract][Full Text] [Related]
5. The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia.
Kim M; Lee EJ; Shin HM; Jung HS; Kim TK; Kim TN; Kwon MJ; Lee SH; Rhee BD; Park JH
J Endocrinol Invest; 2017 Oct; 40(10):1069-1076. PubMed ID: 28391584
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction.
Yasuda S; Kobayashi H; Iwasa M; Kawamura I; Sumi S; Narentuoya B; Yamaki T; Ushikoshi H; Nishigaki K; Nagashima K; Takemura G; Fujiwara T; Fujiwara H; Minatoguchi S
Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1558-65. PubMed ID: 19286954
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression.
Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
Anticancer Agents Med Chem; 2021; 21(1):108-119. PubMed ID: 32807067
[TBL] [Abstract][Full Text] [Related]
8. Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt, and peroxisome proliferator-activated receptor gamma signaling.
Chuang CC; Yang RS; Tsai KS; Ho FM; Liu SH
Endocrinology; 2007 Sep; 148(9):4267-75. PubMed ID: 17540722
[TBL] [Abstract][Full Text] [Related]
9. The peroxisome proliferator-activated receptor γ agonist pioglitazone prevents NF-κB activation in cisplatin nephrotoxicity through the reduction of p65 acetylation via the AMPK-SIRT1/p300 pathway.
Zhang J; Zhang Y; Xiao F; Liu Y; Wang J; Gao H; Rong S; Yao Y; Li J; Xu G
Biochem Pharmacol; 2016 Feb; 101():100-11. PubMed ID: 26673543
[TBL] [Abstract][Full Text] [Related]
10. PPAR-γ agonist pioglitazone prevents apoptosis of endothelial progenitor cells from rat bone marrow.
Zhang HF; Wang L; Yuan HJ; Ma YH; Wang YF; Hu ZY; Su Y; Zhao ZG
Cell Biol Int; 2013 May; 37(5):430-5. PubMed ID: 23504801
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Ihle NT; Lemos R; Wipf P; Yacoub A; Mitchell C; Siwak D; Mills GB; Dent P; Kirkpatrick DL; Powis G
Cancer Res; 2009 Jan; 69(1):143-50. PubMed ID: 19117997
[TBL] [Abstract][Full Text] [Related]
12. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.
Ihle NT; Williams R; Chow S; Chew W; Berggren MI; Paine-Murrieta G; Minion DJ; Halter RJ; Wipf P; Abraham R; Kirkpatrick L; Powis G
Mol Cancer Ther; 2004 Jul; 3(7):763-72. PubMed ID: 15252137
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G; Maffioli P
Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway.
Kole L; Sarkar M; Deb A; Giri B
Pharmacol Rep; 2016 Feb; 68(1):144-54. PubMed ID: 26721366
[TBL] [Abstract][Full Text] [Related]
15. BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner.
Zhang F; Dey D; Bränström R; Forsberg L; Lu M; Zhang Q; Sjöholm A
Am J Physiol Cell Physiol; 2009 Feb; 296(2):C346-54. PubMed ID: 19052259
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3β, Snail1, and β-catenin in renal proximal tubule cells.
Lee YJ; Han HJ
Am J Physiol Renal Physiol; 2010 May; 298(5):F1263-75. PubMed ID: 20015942
[TBL] [Abstract][Full Text] [Related]
17. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.
Howes AL; Chiang GG; Lang ES; Ho CB; Powis G; Vuori K; Abraham RT
Mol Cancer Ther; 2007 Sep; 6(9):2505-14. PubMed ID: 17766839
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, induces dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels.
Omae T; Nagaoka T; Tanano I; Yoshida A
Invest Ophthalmol Vis Sci; 2011 Aug; 52(9):6749-56. PubMed ID: 21757589
[TBL] [Abstract][Full Text] [Related]
19. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients.
Klotz L; Schmidt M; Giese T; Sastre M; Knolle P; Klockgether T; Heneka MT
J Immunol; 2005 Oct; 175(8):4948-55. PubMed ID: 16210596
[TBL] [Abstract][Full Text] [Related]
20. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
Goto T; Nakayama R; Yamanaka M; Takata M; Takazawa T; Watanabe K; Maruta K; Nagata R; Nagamine J; Tsuchida A; Kato H
Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):492-9. PubMed ID: 26011171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
